Cargando…

709. In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam–Durlobactam (ETX2514SUL) Against Pathogenic Burkholderia Species

BACKGROUND: The genus Burkholderia contains several pathogenic species with distinct etiologies, including Burkholderia pseudomallei the biothreat pathogen responsible for melioidosis and Burkholderia mallei which causes glanders. β-Lactams, such as ceftazidime and meropenem, are important therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Donnell, John, Miller, Alita, Lane, Douglas, Panchal, Rekha, Mueller, John P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811307/ http://dx.doi.org/10.1093/ofid/ofz360.777

Ejemplares similares

694. In vitro Antibacterial Activity of Sulbactam–Durlobactam (ETX2514SUL) Against 121 Recent Acinetobacter baumannii Isolated from Patients in India
por: Miller, Alita, et al.
Publicado: (2019)

The Novel β-Lactamase Inhibitor, ETX-2514, in Combination with Sulbactam Effectively Inhibits Acinetobacter baumannii
por: Barnes, Melissa D, et al.
Publicado: (2017)

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent
por: Barnes, Melissa D., et al.
Publicado: (2019)

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function
por: Larson, Kajal, et al.
Publicado: (2023)

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
por: Sagan, Olexiy, et al.
Publicado: (2020)

85. Efficacy of Sulbactam-Durlobactam (SUL-DUR) Compared to Colistin (COL) against Acinetobacter baumannii-calcoaceticus Complex (ABC) Monomicrobial and Polymicrobial Infections in a Phase 3 Trial
por: Miller, Alita, et al.
Publicado: (2023)

2526. Ex Vivo Assessment of Sulbactam-Durlobactam (SUL-DUR) Clearance during Continuous Renal Replacement Therapy (CRRT)
por: Abouelhassan, Yasmeen, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
por: O’Donnell, John, et al.
Publicado: (2019)

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii
por: Moussa, Samir H., et al.
Publicado: (2023)

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
por: Shapiro, Adam B., et al.
Publicado: (2021)

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
por: O’Donnell, John P, et al.
Publicado: (2023)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

1254. In vitro activity of sulbactam-durlobactam against recent global clinical Acinetobacter baumannii-calcoaceticus complex isolates
por: McLeod, Sarah, et al.
Publicado: (2020)

Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species
por: Papp-Wallace, Krisztina M, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282
por: O’Donnell, John, et al.
Publicado: (2020)

2138. In Vitro Susceptibility of Recent Clinical Isolates of P. aeruginosa and Enterobacterales to Imipenem or Meropenem Alone or in Combination with Sulbactam-Durlobactam
por: McLeod, Sarah, et al.
Publicado: (2023)

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review
por: Principe, Luigi, et al.
Publicado: (2022)

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021
por: Karlowsky, James A., et al.
Publicado: (2022)

1293. Sulbactam-durlobactam is active against recent, multi-drug resistant Acinetobacter baumannii clinical isolates from the Middle East
por: Miller, Alita, et al.
Publicado: (2020)

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections
por: Watkins, Richard R, et al.
Publicado: (2023)

2517. Activity of Sulbactam-durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates
por: Huband, Michael D, et al.
Publicado: (2023)

In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam
por: VanNatta, Mollie, et al.
Publicado: (2023)

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece
por: Petropoulou, Dimitra, et al.
Publicado: (2022)

656. Sulbactam-Durlobactam MIC Determination: Comparative Evaluation of the New ETEST(®) SUD to the CLSI 2021 Broth Microdilution Method
por: Sauvonnet, Veronique, et al.
Publicado: (2021)

In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales
por: Fouad, Aliaa, et al.
Publicado: (2023)

Using the Meade ETX: 100 objects you can really see with the mighty etx
por: Weasner, Mike
Publicado: (2002)

In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy
por: Segatore, Bernardetta, et al.
Publicado: (2022)

2121. In vitro Synergy of the Combination of Sulbactam-Durlobactam and Cefepime at Clinically Relevant Concentrations Against A. baumannii, P. aeruginosa, and Enterobacterales
por: Fouad, Aliaa, et al.
Publicado: (2023)

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases
por: Durand-Réville, Thomas F., et al.
Publicado: (2020)

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects
por: Lickliter, Jason D., et al.
Publicado: (2020)

Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization
por: Tiseo, Giusy, et al.
Publicado: (2023)

A randomized, double‐blind, placebo‐ and positive‐controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects
por: O’Donnell, John, et al.
Publicado: (2021)

2515. Evaluation of the Equivalency of the Oxoid Sulbactam-Durlobactam (10/10µg) Antimicrobial Disc to the CLSI M07 Broth Microdilution Frozen Reference Method
por: Hajek, Katie L, et al.
Publicado: (2023)

2514: Governance for a decentralized informatics academic environment
por: Fogg, Thomas, et al.
Publicado: (2018)

ETX1 is over-expressed in the glaucomatous trabecular meshwork
por: Iragavarapu, Saradha, et al.
Publicado: (2009)

2514. Pediatric Medically Attended Shingles in Alberta, Canada 2016; Preliminary Results
por: Booth, Stephanie, et al.
Publicado: (2018)

2514. Real-time Antiretroviral Electronic Adherence Monitoring In Young African American Men Who Have Sex With Men
por: Dworkin, Mark S, et al.
Publicado: (2019)

2514 Disparities in care among patients presenting to the emergency department for nephrolithiasis
por: Schoenfeld, Daniel, et al.
Publicado: (2018)

Recombinant unpurified rETX(H106P)/CTB-rETX(Y196E) protects rabbits against Clostridium perfringens epsilon toxin
por: PENG, Xiaobing, et al.
Publicado: (2021)

1642. A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug-Resistant (MDR) Mycobacterium abscessus (Mab)
por: Dousa, Khalid M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q41gn2etidrnpflgvdmfga8dr0